Insider Transactions in Q1 2024 at Artivion, Inc. (AORT)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 20
2024
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
2,183
-2.55%
|
$43,660
$20.39 P/Share
|
|
Mar 15
2024
|
Andrew M Green VP Regulatory |
SELL
Open market or private sale
|
Direct |
1,462
-3.43%
|
$29,240
$20.0 P/Share
|
|
Mar 14
2024
|
Andrew M Green VP Regulatory |
SELL
Open market or private sale
|
Direct |
3,994
-8.58%
|
$79,880
$20.0 P/Share
|
|
Mar 12
2024
|
Matthew A Getz VP, Human Resources |
SELL
Open market or private sale
|
Direct |
5,000
-10.3%
|
$95,000
$19.94 P/Share
|
|
Mar 05
2024
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
13,996
-1.95%
|
$251,928
$18.72 P/Share
|
|
Mar 05
2024
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
2,380
-1.38%
|
$42,840
$18.72 P/Share
|
|
Mar 05
2024
|
Rochelle L. Maney VP, Quality |
SELL
Open market or private sale
|
Direct |
1,157
-2.43%
|
$20,826
$18.72 P/Share
|
|
Mar 05
2024
|
Matthew A Getz VP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,157
-2.33%
|
$20,826
$18.72 P/Share
|
|
Mar 05
2024
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,022
-1.21%
|
$36,396
$18.72 P/Share
|
|
Mar 05
2024
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
1,506
-1.73%
|
$27,108
$18.72 P/Share
|
|
Mar 05
2024
|
Andrew M Green VP Regulatory |
SELL
Open market or private sale
|
Direct |
1,160
-2.43%
|
$20,880
$18.72 P/Share
|
|
Mar 05
2024
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,152
-0.82%
|
$20,736
$18.72 P/Share
|
|
Mar 01
2024
|
James P Mackin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
28,618
+3.83%
|
-
|
|
Mar 01
2024
|
Jean F Holloway SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
5,724
+3.22%
|
-
|
|
Mar 01
2024
|
Rochelle L. Maney VP, Quality |
BUY
Grant, award, or other acquisition
|
Direct |
3,578
+6.98%
|
-
|
|
Mar 01
2024
|
Matthew A Getz VP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
3,578
+6.72%
|
-
|
|
Mar 01
2024
|
John E Davis Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,724
+3.3%
|
-
|
|
Mar 01
2024
|
Marshall S. Stanton SVP, Clinical & MD Affair |
BUY
Grant, award, or other acquisition
|
Direct |
5,724
+6.18%
|
-
|
|
Mar 01
2024
|
Andrew M Green VP Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
3,578
+6.98%
|
-
|
|
Mar 01
2024
|
Amy Horton VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,578
+2.47%
|
-
|
|
Feb 27
2024
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
325
-0.24%
|
$6,175
$19.83 P/Share
|
|
Feb 27
2024
|
Florian Tyrs VP, Global Operations |
SELL
Open market or private sale
|
Direct |
339
-1.55%
|
$6,441
$19.83 P/Share
|
|
Feb 27
2024
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
485
-0.29%
|
$9,215
$19.83 P/Share
|
|
Feb 27
2024
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
4,837
-0.7%
|
$91,903
$19.83 P/Share
|
|
Feb 27
2024
|
Rochelle L. Maney VP, Quality |
SELL
Open market or private sale
|
Direct |
370
-0.83%
|
$7,030
$19.83 P/Share
|
|
Feb 27
2024
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
584
-0.36%
|
$11,096
$19.83 P/Share
|
|
Feb 27
2024
|
Matthew A Getz VP, Human Resources |
SELL
Open market or private sale
|
Direct |
325
-0.7%
|
$6,175
$19.83 P/Share
|
|
Feb 27
2024
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
465
-0.57%
|
$8,835
$19.83 P/Share
|
|
Feb 27
2024
|
Andrew M Green VP Regulatory |
SELL
Open market or private sale
|
Direct |
421
-0.95%
|
$7,999
$19.83 P/Share
|
|
Feb 26
2024
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,166
-0.8%
|
$43,320
$20.27 P/Share
|
|
Feb 26
2024
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
31,312
-2.29%
|
$626,240
$20.27 P/Share
|
|
Feb 26
2024
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,514
-1.1%
|
$70,280
$20.27 P/Share
|
|
Feb 26
2024
|
Marshall S. Stanton SVP, Clinical & MD Affair |
SELL
Open market or private sale
|
Direct |
3,048
-1.95%
|
$60,960
$20.27 P/Share
|
|
Feb 26
2024
|
Rochelle L. Maney VP, Quality |
SELL
Open market or private sale
|
Direct |
2,315
-2.71%
|
$46,300
$20.27 P/Share
|
|
Feb 26
2024
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
2,880
-0.88%
|
$57,600
$20.27 P/Share
|
|
Feb 26
2024
|
Andrew M Green VP Regulatory |
SELL
Open market or private sale
|
Direct |
2,403
-2.81%
|
$48,060
$20.27 P/Share
|
|
Feb 26
2024
|
Matthew A Getz VP, Human Resources |
SELL
Open market or private sale
|
Direct |
2,313
-2.62%
|
$46,260
$20.27 P/Share
|
|
Feb 26
2024
|
Florian Tyrs VP, Global Operations |
SELL
Open market or private sale
|
Direct |
893
-3.92%
|
$17,860
$20.27 P/Share
|
|
Feb 23
2024
|
Amy Horton VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,677
+4.2%
|
-
|
|
Feb 23
2024
|
James P Mackin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
188,053
+8.58%
|
-
|
|
Feb 23
2024
|
John E Davis Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,856
+7.45%
|
-
|
|
Feb 23
2024
|
Marshall S. Stanton SVP, Clinical & MD Affair |
BUY
Grant, award, or other acquisition
|
Direct |
30,830
+11.95%
|
-
|
|
Feb 23
2024
|
Rochelle L. Maney VP, Quality |
BUY
Grant, award, or other acquisition
|
Direct |
17,677
+12.53%
|
-
|
|
Feb 23
2024
|
Jean F Holloway SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
37,832
+7.29%
|
-
|
|
Feb 23
2024
|
Andrew M Green VP Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
21,380
+14.71%
|
-
|
|
Feb 23
2024
|
Matthew A Getz VP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
20,028
+13.54%
|
-
|
|
Feb 23
2024
|
Lance A Berry Executive VP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
37,000
+31.88%
|
-
|
|
Feb 23
2024
|
Florian Tyrs VP, Global Operations |
BUY
Grant, award, or other acquisition
|
Direct |
6,537
+22.29%
|
-
|
|
Feb 23
2024
|
Robert C Thomson VP Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
8,165
+38.05%
|
-
|
|
Feb 20
2024
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,695
-0.68%
|
$30,510
$18.86 P/Share
|